For research use only. Not for therapeutic Use.
Upacicalcet sodium is an intravenous calcimimetic agent. Upacicalcet suppresses excessive parathyroid hormone (PTH) secretion, thereby lowering blood PTH levels, by acting directly on parathyroid cell membrane calcium-sensing receptors. Upacicalcet can be used for researching the disease of secondary hyperparathyroidism (SHPT)[1].
| Catalog Number | I045648 |
| CAS Number | 2052969-18-1 |
| Synonyms | sodium;(2S)-2-amino-3-[(3-chloro-2-methyl-5-sulfophenyl)carbamoylamino]propanoate |
| Molecular Formula | C11H13ClN3NaO6S |
| Purity | ≥95% |
| InChI | InChI=1S/C11H14ClN3O6S.Na/c1-5-7(12)2-6(22(19,20)21)3-9(5)15-11(18)14-4-8(13)10(16)17;/h2-3,8H,4,13H2,1H3,(H,16,17)(H2,14,15,18)(H,19,20,21);/q;+1/p-1/t8-;/m0./s1 |
| InChIKey | KUQQRUUFBPFDOW-QRPNPIFTSA-M |
| SMILES | CC1=C(C=C(C=C1Cl)S(=O)(=O)O)NC(=O)NCC(C(=O)[O-])N.[Na+] |
| Reference | [1]. Hoy SM. Upacicalcet: First Approval. Drugs. 2021;81(13):1593-1596. |
